Geron Co. (NASDAQ:GERN) Stock Holdings Reduced by Inspire Investing LLC

Inspire Investing LLC lessened its stake in shares of Geron Co. (NASDAQ:GERN) by 26.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 116,860 shares of the biopharmaceutical company’s stock after selling 42,894 shares during the quarter. Inspire Investing LLC’s holdings in Geron were worth $414,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Alternative Investment Advisors LLC. boosted its stake in shares of Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 2,612 shares in the last quarter. Rovin Capital UT ADV boosted its stake in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 3,660 shares in the last quarter. Values First Advisors Inc. boosted its stake in shares of Geron by 13.6% during the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock worth $139,000 after acquiring an additional 3,668 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 4,094 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Geron by 32.6% during the 3rd quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 5,559 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Trading Down 0.3 %

Geron stock opened at $3.01 on Friday. The business has a 50 day moving average price of $3.59 and a two-hundred day moving average price of $4.13. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -9.41 and a beta of 0.55. Geron Co. has a 12 month low of $1.64 and a 12 month high of $5.34.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same period in the prior year, the firm posted ($0.08) EPS. Geron’s quarterly revenue was up 17138.4% compared to the same quarter last year. As a group, equities analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on GERN. Barclays upgraded Geron to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Geron in a research report on Tuesday, December 10th. Needham & Company LLC boosted their price objective on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, Scotiabank assumed coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.